Publications by authors named "Sudhanshu Gogia"
Article Synopsis
- The study investigates the safety and efficacy of efruxifermin, a drug that targets the FGF21 pathway, in patients with non-alcoholic steatohepatitis (NASH) and varying degrees of liver fibrosis during a 96-week phase 2b clinical trial.
- Conducted across 41 clinics in the USA, 128 eligible adult participants with confirmed NASH were randomly assigned to receive either efruxifermin (28 mg or 50 mg) or a placebo, with strict masking of group assignments.
- Primary outcomes focused on the proportion of patients experiencing at least a one-stage improvement in liver fibrosis without worsening NASH symptoms, with a total of 747
Treating hepatocellular carcinoma without liver transplantation.
Curr Gastroenterol Rep
February 2009
Hepatocellular carcinoma, a significant health problem throughout the world, generally occurs in the setting of cirrhosis. Choice of treatment depends on the size and location of the tumor and hepatic reserve. Liver transplantation provides the best chance for long-term survival and can be performed regardless of hepatic reserve, but it requires small tumor sizes and is available to only a few patients.
View Article and Find Full Text PDFBackground: In patients with pancreatic cancer, the presence of malignant mediastinal lymphadenopathy (MML) would preclude definitive resection. A recent study suggested routine evaluation for mediastinal lymph-node metastases in all patients being evaluated for pancreaticobiliary masses. In our practice, we routinely assess for mediastinal lymph-node metastases in all patients undergoing EUS for pancreaticobiliary cancer.
View Article and Find Full Text PDF